Nevro Corp. announced that UnitedHealthcare, the private health insurance company in the United States, will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of PDN for dates of service on or after March 1, 2022. UnitedHealthcare is one of the businesses of UnitedHealth Group, a diversified health care company that provides coverage for more than 39 million commercial health care members.

Under its policy, UnitedHealthcare considers Nevro's U.S. Food and Drug Administration approved high-frequency spinal cord stimulator to be proven and medically necessary for the treatment of diabetic neuropathy when specified criteria are met.